| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 159,395 | 163,353 | 145,534 | 117,085 |
| Cost of product sales | 2,187 | 2,798 | 4,568 | 3,211 |
| Royalty | - | - | - | 17 |
| Research and development | 44,603 | 43,386 | 37,270 | 41,081 |
| Selling, general and administrative | 83,014 | 87,383 | 82,469 | 65,084 |
| Total operating expenses | 129,804 | 133,567 | 124,307 | 109,393 |
| Income from operations | 29,591 | 29,786 | 21,227 | 7,692 |
| Interest income | 2,238 | 2,516 | 3,024 | 3,591 |
| Interest expense | 19,661 | 21,582 | 23,494 | 24,828 |
| Foreign currency gains (losses), net | 35 | -63 | 1 | 98 |
| Loss on extinguishment of debt | -2,740 | -4,171 | - | - |
| Other income | 2,667 | - | - | - |
| Total other expense, net | -17,461 | -23,300 | -20,469 | - |
| Income (loss) before income taxes | 12,130 | 6,486 | 758 | -13,447 |
| Income tax expense (benefit) | -769 | 1,401 | 726 | 586 |
| Net income (loss) | 12,899 | 5,085 | 32 | -14,033 |
| Unrealized gain on available for sale investments | - | - | - | 1,173 |
| Foreign currency translation adjustment | -523 | 702 | 366 | 563 |
| Unrealized gain (loss) on available for sale investments | 17 | -188 | -155 | - |
| Total other comprehensive income (loss) | - | - | 211 | - |
| Total other comprehensive (loss) income | -506 | 514 | - | - |
| Net comprehensive income (loss) | 12,393 | 5,599 | 243 | -12,297 |
| Basic net loss per common share (in usd per share) | 0.06 | 0.02 | 0 | -0.07 |
| Diluted net loss per common share (in usd per share) | 0.06 | 0.02 | 0 | -0.07 |
| Weighted average shares outstanding, basic (in shares) | 210,176,000 | 209,519,000 | 208,882,000 | 206,905,000 |
| Weighted average shares outstanding, diluted (in shares) | 219,885,000 | 219,886,000 | 215,261,000 | 206,905,000 |
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)